DE2460891C2 - 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel - Google Patents
1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende ArzneimittelInfo
- Publication number
- DE2460891C2 DE2460891C2 DE2460891A DE2460891A DE2460891C2 DE 2460891 C2 DE2460891 C2 DE 2460891C2 DE 2460891 A DE2460891 A DE 2460891A DE 2460891 A DE2460891 A DE 2460891A DE 2460891 C2 DE2460891 C2 DE 2460891C2
- Authority
- DE
- Germany
- Prior art keywords
- aminomethyl
- acid
- acids
- general formula
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Description
1 -Aminomethyl-1 -cyclohexanessigsäure D
wird mit 50 ml 20%iger Salzsäure 3 Stunden zum Rückfluß erhitzt Nach Erkalten der Lösung entfernt man durch dreimalige Extraktion mit je 100 ml Chloroform das als Nebenprodukt gebildete 1 -Aminomethyl- l-cyclohexanessigsäurelactam und engt die salzsaure wäßrige Lösung im Vakuum ein, wobei die 1-Aminomethyl-1-cyclohexanessigsäure als Hydrochiorid kristallisiert(Fp. 117—118°C aus Aceton/Methanol/ Äther.)
Gef.: C 51,03 H 8,56 Cl 1634 N 6,84%
Gef.: C 63,20 H 9,61 N 7,95 0 19,02%
1 -Aminomethyl-1 -cyclohexanessigsäureäthylester 5j
Gef.: C 55.93 H 9.28 N 5,94%
1 -Aminomethyl-1 -cycloheptanessigsäure
Gef.: C 53,29 H 9,03 Cl 15,73 N 6,16 O 15,77%
Variante A
Gef.: C 60,78 H 9,37 N 8,93 O19,9C%
1 -Aminomethyl-1 -cyclohexanessigsäure
Ber.: C 53.46 H 8,47%
Gef.: C 53,48 H 8,28%
1 -Aminomethyl- l-cyclohexanessigsäuremethylester
(Fp. 150- 1520C) als Hydrochlorid.
Gef.: C 53,26 H 8,68 Cl 1539 N 6,23%
Gef.: C 58.21 H 9,69 Cl 13.45 N 5,36%
Natriumsalz der
Gef.: C!. 4,55 H 10,32 N 7,35%
1-Aminomethyl-i-cycloheptanessigsäuremethylester
Gef.: C 55,70 H 9,24 Cl 14,94 N 6,05%
vom Schmp. 116-118°C.
Gef.: C 60,97 H 8,68 N 3,91%
Gef.: C 53,44 H 6,77 N 4,58%
Gef.: C 5935 H 7,99 N 3,88%
antikonvulsiven Wirkung
B
C
D
<30
<60
100
= 1 -Aminomethyl-1 -cyclopentanessigsäure
D = Valproinsäure (als Natriumsalz)
Claims (1)
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2460891A DE2460891C2 (de) | 1974-12-21 | 1974-12-21 | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE19752543821 DE2543821C2 (de) | 1974-12-21 | 1975-10-01 | Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel |
MX584675U MX4721E (es) | 1974-12-21 | 1975-12-11 | Procedimiento para la preparacion de aminoacidos ciclicos |
MX584775U MX4691E (es) | 1974-12-21 | 1975-12-11 | Procedimiento para la preparacion de aminoacidos ciclicos |
GB5119375A GB1465229A (en) | 1974-12-21 | 1975-12-15 | Cyclic amino acids |
IE2736/75A IE42382B1 (en) | 1974-12-21 | 1975-12-15 | Cyclic amino acids |
FR7538818A FR2294697A1 (fr) | 1974-12-21 | 1975-12-18 | Nouveaux acides amino cycliques |
BE6045299A BE836835A (fr) | 1974-12-21 | 1975-12-18 | Nouveaux acides amino cycliques |
CH1645175A CH612664A5 (de) | 1974-12-21 | 1975-12-18 | |
CH430778A CH612665A5 (de) | 1974-12-21 | 1975-12-18 | |
CH430878A CH612666A5 (de) | 1974-12-21 | 1975-12-18 | |
LU74058A LU74058A1 (de) | 1974-12-21 | 1975-12-19 | |
ES443723A ES443723A1 (es) | 1974-12-21 | 1975-12-19 | Procedimiento de preparacion de aminoacidos ciclicos. |
FI753613A FI62282C (fi) | 1974-12-21 | 1975-12-19 | Foerfarande foer framstaellning av terapeutiskt anvaendbara cyliska aminosyror |
SE7514442A SE423385B (sv) | 1974-12-21 | 1975-12-19 | Forfarande for framstellning av cykloalitatiska aminosyror och estrar derav |
AU87741/75A AU488009B2 (en) | 1974-12-21 | 1975-12-19 | Cyclic amino-acids |
DK581475A DK147706C (da) | 1974-12-21 | 1975-12-19 | Analogifremgangsmaade til fremstilling af cycliske aminocarboxylsyrer eller farmakologisk acceptable salte deraf |
CA242,147A CA1052811A (en) | 1974-12-21 | 1975-12-19 | Cyclic amino-acids |
NLAANVRAGE7514900,A NL181006C (nl) | 1974-12-21 | 1975-12-20 | Werkwijze voor de bereiding of vervaardiging van een geneesmiddel voor de behandeling van epilepsie, duizeligheid, hypokinesis, schedeltrauma en geriatrische ziekten, alsmede werkwijze voor de bereiding van een 4-aminoboterzuur derivaat. |
AT975075A AT340892B (de) | 1974-12-21 | 1975-12-22 | Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen |
JP15319475A JPS5324064B2 (de) | 1974-12-21 | 1975-12-22 | |
US05/645,724 US4024175A (en) | 1974-12-21 | 1975-12-31 | Cyclic amino acids |
US05/791,677 US4087544A (en) | 1974-12-21 | 1977-04-28 | Treatment of cranial dysfunctions using novel cyclic amino acids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2460891A DE2460891C2 (de) | 1974-12-21 | 1974-12-21 | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2460891A1 DE2460891A1 (de) | 1976-07-01 |
DE2460891C2 true DE2460891C2 (de) | 1982-09-23 |
Family
ID=5934284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2460891A Expired DE2460891C2 (de) | 1974-12-21 | 1974-12-21 | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
Country Status (16)
Country | Link |
---|---|
US (1) | US4024175A (de) |
JP (1) | JPS5324064B2 (de) |
AT (1) | AT340892B (de) |
BE (1) | BE836835A (de) |
CA (1) | CA1052811A (de) |
CH (3) | CH612665A5 (de) |
DE (1) | DE2460891C2 (de) |
DK (1) | DK147706C (de) |
ES (1) | ES443723A1 (de) |
FI (1) | FI62282C (de) |
FR (1) | FR2294697A1 (de) |
GB (1) | GB1465229A (de) |
IE (1) | IE42382B1 (de) |
LU (1) | LU74058A1 (de) |
NL (1) | NL181006C (de) |
SE (1) | SE423385B (de) |
Families Citing this family (220)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2611690A1 (de) * | 1976-03-19 | 1977-09-22 | Goedecke Ag | Cyclische sulfonyloxyimide |
JPS5776189U (de) * | 1980-10-28 | 1982-05-11 | ||
JPS5847580U (ja) * | 1981-09-28 | 1983-03-30 | 本田技研工業株式会社 | 車両用荷物箱の取付構造 |
JPS6152583U (de) * | 1984-09-11 | 1986-04-09 | ||
JPS61139881U (de) * | 1985-02-21 | 1986-08-29 | ||
US4876279A (en) * | 1986-05-05 | 1989-10-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4960931A (en) * | 1988-05-02 | 1990-10-02 | Warner-Lambert Company | Gabapentin mohohydrate and a process for producing the same |
US4894476A (en) * | 1988-05-02 | 1990-01-16 | Warner-Lambert Company | Gabapentin monohydrate and a process for producing the same |
YU162789A (en) * | 1988-09-01 | 1990-12-31 | Lonza Ag | 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones |
US5132451A (en) * | 1989-08-25 | 1992-07-21 | Warner-Lambert Company | Process for cyclic amino acid anticonvulsant compounds |
US5319135A (en) * | 1989-08-25 | 1994-06-07 | Warner-Lambert Company | Process for cyclic amino acid anticonvulsant compounds |
DE3928184A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte |
DE3928183A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
DE3928182A1 (de) * | 1989-08-25 | 1991-02-28 | Goedecke Ag | Verfahren zur herstellung von gabapentin |
FI107914B (fi) * | 1989-08-25 | 2001-10-31 | Warner Lambert Co | Parannettu menetelmä syklisten aminohappoyhdisteiden valmistamiseksi ja menetelmässä käytettävä välituote |
US5136091A (en) * | 1989-11-16 | 1992-08-04 | Lonza Ltd. | Process for the production of 1-(aminomethyl) cyclohexane acetic acid |
GB8925933D0 (en) * | 1989-11-16 | 1990-01-04 | Pfizer Ltd | Glutaric acid derivatives and preparation thereof |
US5157138A (en) * | 1989-11-16 | 1992-10-20 | Pfizer, Inc. | Glutaric acid derivatives and preparation thereof |
US5260467A (en) * | 1989-11-16 | 1993-11-09 | Pfizer Inc. | Glutaric acid derivatives and preparation thereof |
FI905584A (fi) * | 1989-11-16 | 1991-05-17 | Lonza Ag | Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra. |
US5149870A (en) * | 1989-11-16 | 1992-09-22 | Lonza Ltd. | Process for the production of 1-(aminomethyl)cyclohexane acetic acid |
US5084479A (en) * | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
US5025035A (en) * | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
DE69712877T2 (de) * | 1996-02-07 | 2002-11-14 | Warner Lambert Co | Zyklischaminosäure als pharmazeutische mittel |
ATE207878T1 (de) * | 1996-03-14 | 2001-11-15 | Warner Lambert Co | Zyklische aminosäure als pharmazeutische wirkstoffe |
CZ287598A3 (cs) * | 1996-03-14 | 1999-02-17 | Warner-Lambert Company | Přemostěné cyklické aminokyseliny |
SI0934061T1 (en) | 1996-07-24 | 2003-10-31 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
CA2263663C (en) * | 1996-10-23 | 2006-05-30 | Justin Stephen Bryans | Substituted gamma aminobutyric acids as pharmaceutical agents |
US6255526B1 (en) | 1996-12-24 | 2001-07-03 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
IL119890A (en) * | 1996-12-24 | 2002-03-10 | Teva Pharma | Gabapentin form iii and preparation of gabapentin form ii |
US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
WO1999008667A2 (en) | 1997-08-19 | 1999-02-25 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of ***e or other psychomotor stimulants |
KR100537707B1 (ko) * | 1997-09-08 | 2005-12-20 | 워너-램버트 캄파니 엘엘씨 | 항간질 화합물을 포함하는 진통제 조성물 및 이의 사용 방법 |
AU9318398A (en) | 1997-10-07 | 1999-04-27 | Warner-Lambert Company | Process for preparing a cyclic amino acid anticonvulsant compound |
NZ503651A (en) * | 1997-10-27 | 2002-09-27 | Warner Lambert Co | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents |
US6984659B2 (en) * | 1997-11-18 | 2006-01-10 | Klinikum Der Albert-Ludwigs Universitaet | 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level |
US6545022B1 (en) | 1997-12-16 | 2003-04-08 | Pfizer Inc. | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
BR9813656A (pt) | 1997-12-16 | 2000-10-10 | Warner Lambert Co | Aminas como agentes farmacêuticos |
CN1495160A (zh) * | 1997-12-16 | 2004-05-12 | ��ʲ | 1-取代-1-氨基甲基-环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
EP1047414A1 (de) * | 1998-01-23 | 2000-11-02 | Warner-Lambert Company | Gabapentin und seine derivate zur behandlungen von muskel und skelett-schmerzen |
EP0974351A3 (de) * | 1998-04-24 | 2000-12-13 | Jouveinal | Arzneimittel zur Vorbeugung und Behandlung von Magendarmschäden |
WO1999059572A1 (en) * | 1998-05-15 | 1999-11-25 | Warner-Lambert Company | Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same |
EP1077692B1 (de) | 1998-05-15 | 2004-07-28 | Warner-Lambert Company LLC | Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung |
ES2137137B1 (es) * | 1998-05-25 | 2000-08-16 | Medichem Sa | Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica. |
KR20010043831A (ko) | 1998-05-26 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물 |
ITMI981535A1 (it) * | 1998-07-03 | 2000-01-03 | Zambon Spa | Processo per la preparazione di gabapentina |
US20030045500A1 (en) * | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
FR2781793B1 (fr) | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
HU225502B1 (en) * | 1998-12-29 | 2007-01-29 | Richter Gedeon Vegyeszet | Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates |
IT1311984B1 (it) | 1999-03-26 | 2002-03-22 | Bioindustria Lab Italiano Medi | Procedimento per la preparzione di gabapentin. |
EP1169060B1 (de) * | 1999-04-09 | 2005-08-31 | Euro-Celtique S.A. | Natrium kanalblocker zusammensetzungen und deren verwendung |
US6710190B1 (en) * | 1999-05-28 | 2004-03-23 | Warner-Lambert Company | 3-heteroarylalkyl substituted gaba analogs |
BR0011039A (pt) * | 1999-05-28 | 2002-02-26 | Warner Lambert Co | Análogos de gaba substituìdos com 3-heteroarilalquila |
US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
CA2374755C (en) * | 1999-06-10 | 2010-03-30 | Warner-Lambert Company | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
US6294198B1 (en) | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
HN2000000224A (es) | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
GB2362646A (en) * | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
EP1289364B1 (de) | 2000-06-16 | 2003-12-10 | Teva Pharmaceutical Industries Ltd. | Stabiles gabapentin, das mehr als 20 ppm chlor enthält |
EP1384473A1 (de) * | 2000-06-16 | 2004-01-28 | Teva Pharmaceutical Industries Ltd. | Stabiles Gabapentin das mehr als 20 ppm Chlor enthält |
AU2001266992B8 (en) * | 2000-06-16 | 2005-12-01 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin having pH within a controlled range |
NZ522480A (en) * | 2000-06-26 | 2005-06-24 | Warner Lambert Co | Gabapentin analogues for sleep disorders |
GB2364049A (en) * | 2000-06-28 | 2002-01-16 | Warner Lambert Co | Cyclic ketones and their use in the synthesis of amino acids |
AU1497802A (en) * | 2000-09-14 | 2002-03-26 | Gruenenthal Chemie | Ss-thio-amino acids |
EP1361847A2 (de) * | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Gallensäurekonjugate zur bereitstellung anhaltender systemischer arneimittelkonzentrationen |
US6992076B2 (en) * | 2000-10-06 | 2006-01-31 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
IT1319234B1 (it) * | 2000-10-23 | 2003-09-26 | Zambon Spa | Processo di preparazione di gabapentina. |
GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
EP1337506A4 (de) | 2000-11-02 | 2005-05-04 | Teva Pharma | Verbessertes verfahren zur herstellung eines gabapentin-zwischenprodukts |
DOP2001000289A (es) * | 2000-11-30 | 2003-02-15 | Pfizer Prod Inc | Combinación de agonistas de gaba e inhibidores de sorbitol- deshidrogenasa |
AU2002215160A1 (en) * | 2000-11-30 | 2002-06-11 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
IT1319674B1 (it) * | 2000-12-01 | 2003-10-23 | Erregierre Spa | Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico. |
WO2002074727A1 (en) * | 2001-03-16 | 2002-09-26 | Solchem Italiana S.P.A. | A process for the preparation of cyclic amino acids |
ITMI20011132A1 (it) | 2001-05-29 | 2002-11-29 | Procos Spa | Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100344A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
HUP0400183A2 (hu) * | 2001-06-11 | 2004-07-28 | Xenoport Inc. | Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái |
IL144066A0 (en) * | 2001-06-28 | 2002-04-21 | Bromine Compounds Ltd | Process for the preparation of 1,1-cyclohexane diacetic monoamide |
ITMI20011772A1 (it) | 2001-08-10 | 2003-02-10 | A M S A Anonima Materie Sint E | Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide) |
KR100890875B1 (ko) * | 2001-09-03 | 2009-03-31 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도 |
US6800782B2 (en) * | 2001-10-09 | 2004-10-05 | Warner-Lambert Co. | Anhydrous crystalline forms of gabapentin |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US20030119908A1 (en) * | 2001-12-21 | 2003-06-26 | Zambon Group S.P.A. | Stable gabapentin compositions |
ITMI20012750A1 (it) | 2001-12-21 | 2003-06-21 | Procos Spa | Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura |
WO2003063845A1 (en) * | 2002-01-31 | 2003-08-07 | Warner-Lambert Company Llc | Alpha 2 delta ligands to treat tinnitus |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
AU2003222033A1 (en) | 2002-03-20 | 2003-10-08 | Xenoport | Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof |
AU2003262383A1 (en) * | 2002-04-16 | 2003-11-03 | Taro Pharmaceutical Industries Ltd. | Process for preparing gabapentin |
US20050153928A1 (en) * | 2002-05-07 | 2005-07-14 | Holick Michael F. | Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof |
WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
AU2003239752A1 (en) * | 2002-06-27 | 2004-01-19 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
CA2395931A1 (en) * | 2002-08-07 | 2004-02-07 | Bernard Charles Sherman | Solid compositions comprising gabapentin having improved stability |
US7053122B2 (en) * | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
US20040092522A1 (en) * | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
US20040092591A1 (en) * | 2002-08-15 | 2004-05-13 | Blakemore David Clive | Therapeutic use of fused bicyclic or tricyclic amino acids |
US20040092498A1 (en) * | 2002-08-16 | 2004-05-13 | David Blakemore | Substituted glycine derivatives for use as medicaments |
ITMI20022071A1 (it) * | 2002-10-01 | 2004-04-02 | Erregierre Spa | Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato. |
US7659305B2 (en) * | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
AU2002356424A1 (en) * | 2002-11-18 | 2004-06-15 | Nicholas Piramal India Limited | Improved process for preparation of gabapentin |
WO2004046108A1 (en) * | 2002-11-20 | 2004-06-03 | Hikal Ltd. | An improved process for the preparation of gabalactam |
US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
AU2003297927A1 (en) * | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US20040180958A1 (en) * | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
MXPA05006209A (es) * | 2002-12-13 | 2005-08-19 | Warner Lambert Co | Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados. |
JP2006511605A (ja) * | 2002-12-13 | 2006-04-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 線維筋痛及び他の関連障害のためのガバペンチン類縁体 |
RU2353358C2 (ru) | 2002-12-13 | 2009-04-27 | Уорнер-Ламберт Компани Ллс | Производные прегабалина для лечения приливов |
RU2331438C2 (ru) | 2002-12-13 | 2008-08-20 | Уорнер-Ламберт Компани Ллс | Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей |
GB0301143D0 (en) * | 2003-01-17 | 2003-02-19 | Amedis Pharm Ltd | Compounds and their use |
RU2312853C2 (ru) * | 2003-01-22 | 2007-12-20 | Уорнер-Ламберт Компани Ллс | ПРОИЗВОДНЫЕ ЦИКЛОПРОПИЛ-β-АМИНОКИСЛОТЫ |
EP1603890A1 (de) * | 2003-03-07 | 2005-12-14 | Warner-Lambert Company LLC | Tetrazol und oxadiazolon-substituierte &bgr;-aminosäurederivate |
WO2004093827A2 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
WO2004093866A1 (en) * | 2003-03-25 | 2004-11-04 | Kiel Laboratories, Inc. | Process for preparing phenolic acid salts of gabapentin |
EP1628656B1 (de) * | 2003-03-25 | 2008-10-15 | Kiel Laboratories, Inc. | Gabapentintannat in flüssigen und/oder halbfesten dosierformen |
MXPA05010515A (es) * | 2003-03-31 | 2006-03-10 | Xenoport Inc | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. |
US20040214893A1 (en) * | 2003-04-11 | 2004-10-28 | Matthew Peterson | Gabapentin compositions |
ITMI20030825A1 (it) * | 2003-04-18 | 2004-10-19 | Farchemia Srl | Procedimento per la preparazione di gabapentin esente da |
US7439387B2 (en) * | 2003-04-21 | 2008-10-21 | Matrix Laboratories Ltd. | Process for the preparation of Gabapentin form-II |
MXPA05012317A (es) * | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas. |
JP2006527595A (ja) * | 2003-06-19 | 2006-12-07 | ファイザー・プロダクツ・インク | 1−シアノシクロヘキサンアセティックアシッドの生体触媒による調製 |
US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
WO2005046566A2 (en) * | 2003-08-04 | 2005-05-26 | Sun Pharmaceutical Industries Limited | Stable gabapentin containing composition |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
JP2007505149A (ja) * | 2003-09-11 | 2007-03-08 | ゼノポート,インコーポレイティド | ギャバ類似体のプロドラッグを用いる尿失禁の治療および/あるいは予防 |
CA2538412A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
EP1663398B1 (de) | 2003-09-12 | 2009-11-25 | Pfizer Limited | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
NZ545989A (en) * | 2003-09-17 | 2009-10-30 | Xenoport Inc | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
MXPA06004088A (es) * | 2003-10-14 | 2006-06-27 | Xenoport Inc | Forma cristalina de un analogo del acido gamma-aminobutirico. |
ITMI20032165A1 (it) * | 2003-11-11 | 2005-05-12 | Zambon Spa | Processo di preparazione di gabapentina |
DK1691811T3 (da) | 2003-12-11 | 2014-10-20 | Sunovion Pharmaceuticals Inc | Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression |
EP1737466A1 (de) * | 2004-01-29 | 2007-01-03 | Pfizer Products Inc. | KOMBINATION VON Y-AMINOBUTTERSÄURE-MODULATOREN UND 5HT-1b REZEPTOR-ANTAGONISTEN |
US20050187295A1 (en) * | 2004-02-19 | 2005-08-25 | Surendra Kalyan | Processes for the preparation of gabapentin |
EP1763503A1 (de) * | 2004-03-17 | 2007-03-21 | Hikal Limited | 4-t-butylgabapentin und dessen synthese |
ITMI20040579A1 (it) * | 2004-03-25 | 2004-06-25 | Zambon Spa | Processo di preparazione di gabapentina |
WO2005102366A2 (en) * | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Lithium combinations, and uses related thereto |
RU2006143659A (ru) * | 2004-06-09 | 2008-06-20 | Пфайзер Инк. (Uпфайзер Инк. (Us)S) | Применение ребоксетина для лечения боли |
GB0416228D0 (en) * | 2004-07-20 | 2004-08-25 | Sandoz Ind Products S A | Process for the preparation of gabapentin |
GB0419849D0 (en) * | 2004-09-07 | 2004-10-13 | Pfizer Ltd | Pharmaceutical combination |
CN101018546B (zh) * | 2004-09-10 | 2013-06-12 | 纽朗制药有限公司 | 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类 |
RU2440112C2 (ru) | 2004-11-04 | 2012-01-20 | Ксенопорт, Инк. | Пероральная дозированная форма габапентина замедленного высвобождения |
EP1928437A2 (de) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenese mittels muscarinrezeptormodulation |
EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
PL1931335T3 (pl) * | 2005-09-23 | 2010-07-30 | Janssen Pharmaceutica Nv | Modulatory heksahydrocyklooktylopirazolokannabinoidowe |
US8378096B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
CN101312952B (zh) * | 2005-09-23 | 2012-12-26 | 詹森药业有限公司 | 四氢-环戊二烯并吡唑***素调节剂 |
US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
ATE534387T1 (de) * | 2005-09-23 | 2011-12-15 | Janssen Pharmaceutica Nv | Hexahydro-cycloheptapyrazol-cannabinoid- modulatoren |
US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
EP1940389A2 (de) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation von neurogenese durch pde-hemmung |
EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
US20070117858A1 (en) * | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
EP1979593B1 (de) * | 2006-02-03 | 2017-12-06 | Rolls-Royce Corporation | Gasturbinenantriebsstoffsystem mit treibstoffmessendem ventil |
EP1820502A1 (de) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate |
WO2007095513A1 (en) * | 2006-02-14 | 2007-08-23 | Janssen Pharmaceutica, Nv | Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators |
MX2008011396A (es) * | 2006-03-06 | 2008-09-18 | Pfizer Prod Inc | Ligandos alfa-2-delta para sueño no reconstituyente. |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007112402A1 (en) * | 2006-03-27 | 2007-10-04 | Janssen Pharmaceutica N.V. | Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators |
US20070254911A1 (en) * | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
EP2026813A2 (de) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5-ht-rezeptor-vermittelte neurogenese |
US7442834B2 (en) * | 2006-06-12 | 2008-10-28 | Zhejiang Chiral Medicine Chemicals Co., Ltd. | Process suitable for industrial scale production of gabapentin |
JP5144656B2 (ja) * | 2006-06-30 | 2013-02-13 | ザック システム エス.ピー.エー. | ガバペンチンの調製プロセス |
WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CN101652133A (zh) * | 2006-12-08 | 2010-02-17 | 克塞诺波特公司 | Gaba类似物的前药用于治疗疾病的用途 |
CN101600458A (zh) | 2006-12-22 | 2009-12-09 | 瑞蔻达蒂爱尔兰有限公司 | 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗 |
US20100145057A1 (en) * | 2007-03-15 | 2010-06-10 | Sun Pharma Advanced Research Company Ltd. | Novel prodrugs |
WO2008157408A2 (en) * | 2007-06-15 | 2008-12-24 | Xenoport, Inc. | Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
US20090062392A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched gabapentin |
WO2009061934A1 (en) * | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
US7872046B2 (en) * | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
JP5563483B2 (ja) * | 2008-01-25 | 2014-07-30 | ゼノポート,インコーポレイティド | アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解 |
EP2116539A1 (de) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
US20100190752A1 (en) | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
BRPI0919811B1 (pt) | 2008-10-08 | 2022-04-19 | Xgene Pharmaceutical Inc | Conjugados de gaba e métodos de uso dos mesmos |
WO2010099200A1 (en) | 2009-02-24 | 2010-09-02 | Nektar Therapeutics | Oligomer-amino acid conjugates |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
AU2010328186B2 (en) | 2009-12-08 | 2014-12-18 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
EP2353591A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon |
EP2368872A1 (de) | 2010-03-25 | 2011-09-28 | Serichim S.r.l. | Verfahren zur Herstellung von Gabapentin |
EP2388005A1 (de) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie |
IN2012MN02923A (de) | 2010-06-01 | 2015-06-05 | Rubicon Res Private Ltd | |
US8431739B2 (en) | 2010-06-14 | 2013-04-30 | Divi's Laboratories, Ltd. | Process for the preparation of gabapentin |
BR112013000164B1 (pt) | 2010-07-30 | 2021-11-23 | Toray Industries, Inc | Agente terapêutico ou agente profilático |
EP2415471A1 (de) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie |
JP2013216580A (ja) * | 2010-08-06 | 2013-10-24 | Kyorin Pharmaceutical Co Ltd | ビシクロ[2.2.2]オクチルアミン誘導体の製造方法 |
EP2524694A1 (de) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes |
EP2530072A1 (de) | 2011-06-03 | 2012-12-05 | Lacer, S.A. | Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung |
US9066853B2 (en) | 2013-01-15 | 2015-06-30 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable fiber |
ITMI20131757A1 (it) | 2013-10-22 | 2015-04-23 | Zach System Spa | Processo di preparazione di gabapentina |
CN105392891B (zh) | 2013-11-01 | 2021-02-12 | 株式会社糖锁工学研究所 | 具有硫醇基的d-型或l-型氨基酸衍生物的制造方法 |
MA39146A1 (fr) | 2013-12-17 | 2017-11-30 | Esteve Labor Dr | Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma |
MA39147B1 (fr) | 2013-12-17 | 2019-12-31 | Esteve Labor Dr | Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma |
EP2923694B1 (de) | 2014-03-27 | 2018-11-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orale flüssige pharmazeutische lösung von gabapentin |
CA3046846A1 (en) | 2016-12-16 | 2018-06-21 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
EP3818981B1 (de) | 2018-07-04 | 2024-02-21 | Amézcua Amézcua, Federico | Synergistische pharmazeutische zusammensetzung des aktiven enantiomers (s)-ketorolac und gabapentin zur behandlung von neuropathischem schmerz |
US10399926B1 (en) | 2018-08-01 | 2019-09-03 | Divi's Laboratories Ltd. | Process for the preparation of gabapentin |
WO2020074944A1 (en) | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
WO2021079887A1 (ja) | 2019-10-25 | 2021-04-29 | 国立大学法人京都大学 | タウオパチーの予防又は治療剤 |
EP4015494A1 (de) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Verfahren zur herstellung von löslichen salzen von inositolphosphaten |
-
1974
- 1974-12-21 DE DE2460891A patent/DE2460891C2/de not_active Expired
-
1975
- 1975-12-15 GB GB5119375A patent/GB1465229A/en not_active Expired
- 1975-12-15 IE IE2736/75A patent/IE42382B1/en unknown
- 1975-12-18 CH CH430778A patent/CH612665A5/xx not_active IP Right Cessation
- 1975-12-18 CH CH1645175A patent/CH612664A5/xx not_active IP Right Cessation
- 1975-12-18 FR FR7538818A patent/FR2294697A1/fr active Granted
- 1975-12-18 CH CH430878A patent/CH612666A5/xx active Protection Beyond IP Right Term
- 1975-12-18 BE BE6045299A patent/BE836835A/xx not_active IP Right Cessation
- 1975-12-19 DK DK581475A patent/DK147706C/da not_active IP Right Cessation
- 1975-12-19 FI FI753613A patent/FI62282C/fi not_active IP Right Cessation
- 1975-12-19 SE SE7514442A patent/SE423385B/xx active Protection Beyond IP Right Term
- 1975-12-19 LU LU74058A patent/LU74058A1/xx unknown
- 1975-12-19 ES ES443723A patent/ES443723A1/es not_active Expired
- 1975-12-19 CA CA242,147A patent/CA1052811A/en not_active Expired
- 1975-12-20 NL NLAANVRAGE7514900,A patent/NL181006C/xx not_active IP Right Cessation
- 1975-12-22 AT AT975075A patent/AT340892B/de active Protection Beyond IP Right Term
- 1975-12-22 JP JP15319475A patent/JPS5324064B2/ja not_active Expired
- 1975-12-31 US US05/645,724 patent/US4024175A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
NICHTS-ERMITTELT |
Also Published As
Publication number | Publication date |
---|---|
FI753613A (de) | 1976-06-22 |
JPS5188940A (de) | 1976-08-04 |
NL181006B (nl) | 1987-01-02 |
DK147706B (da) | 1984-11-19 |
CA1052811A (en) | 1979-04-17 |
JPS5324064B2 (de) | 1978-07-18 |
IE42382L (en) | 1976-06-21 |
CH612664A5 (de) | 1979-08-15 |
GB1465229A (en) | 1977-02-23 |
ATA975075A (de) | 1977-05-15 |
LU74058A1 (de) | 1976-07-20 |
AT340892B (de) | 1978-01-10 |
DK147706C (da) | 1985-05-13 |
NL7514900A (nl) | 1976-06-23 |
CH612666A5 (de) | 1979-08-15 |
FI62282B (fi) | 1982-08-31 |
FR2294697B1 (de) | 1978-07-28 |
BE836835A (fr) | 1976-06-18 |
FR2294697A1 (fr) | 1976-07-16 |
NL181006C (nl) | 1987-06-01 |
IE42382B1 (en) | 1980-07-30 |
US4024175A (en) | 1977-05-17 |
ES443723A1 (es) | 1977-04-16 |
DK581475A (da) | 1976-01-22 |
SE7514442L (sv) | 1976-06-22 |
SE423385B (sv) | 1982-05-03 |
DE2460891A1 (de) | 1976-07-01 |
AU8774175A (en) | 1977-06-23 |
FI62282C (fi) | 1982-12-10 |
CH612665A5 (de) | 1979-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2460891C2 (de) | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE965036C (de) | Verfahren zur Herstellung von p-(Bis-2-chloraethyl-amino)-ª-phenyl-alanin | |
DE3001328C2 (de) | ||
DE2228012B2 (de) | -Aminophenylacetamido] -penicülansäure und Verfahren zu seiner Herstellung | |
EP0109020A2 (de) | Neue Derivate tricyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung, sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung | |
DE3303112A1 (de) | Verfahren zur racemattrennung optisch aktiver bicyclischer imino-(alpha)-carbonsaeuren | |
EP0039844A2 (de) | Verfahren zur Herstellung von O-substituierten Derivaten des (+)-Cyanidan-3-ols | |
DE1645971A1 (de) | Verfahren zur Herstellung von therapeutisch wertvollen (Indazol-3-yl)-oxyalkansaeuren | |
DE2221912A1 (de) | Penicillinester,deren Salze und Verfahren zu ihrer Herstellung | |
EP0048911B1 (de) | O-substituierte alpha-Ketocarbonsäureoxime, Verfahren zu ihrer Herstellung, sowie Arzneimittel, die diese Verbindungen enthalten | |
EP0431371B1 (de) | 3-Aminopyrrole, Verfahren zu ihrer Herstellung und ihre Verwendung als Antikonvulsiva | |
EP0094633B1 (de) | Spiro-2-aza-alkan-3-carbonitrile, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE2543821C2 (de) | Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel | |
DE1620295C3 (de) | Isochinolo eckige Klammer auf 2,1-d eckige Klammer zu benzo eckige Klammer auf 1,4 eckige Klammer zu diazepin-6-one | |
CH610330A5 (en) | Process for the preparation of novel ergopeptins | |
DE2520131C3 (de) | 1,1,-Disubstituierte Octahydro-indolo[2,3-a]chinolizine und verfahren zu deren Herstellung | |
DE2855853C2 (de) | N-(1-Benzyl-2-methyl-3-pyrrolidinyl)-5-chlor-2-methoxy-4-methylaminobenzamid dessen Säureadditionssalze, Verfahren zu deren Herstellung und ihre Verwendung | |
AT390791B (de) | Verfahren zur herstellung neuer kondensierter as-triazinium-derivate sowie von deren isomeren | |
DE2626467A1 (de) | Cyclische aminosaeure-derivate | |
CH649551A5 (de) | 3-substituierte-tetrahydro-pyrrolo(1,2-a)pyrimidine, verfahren zu ihrer herstellung sowie ihrer verwendung in pharmazeutischen praeparaten. | |
DE968561C (de) | Verfahren zur Herstellung von am Aminostickstoff substituierten Monoaminoacylaniliden | |
DE1595891C3 (de) | 6-(ß-Dimethylaminopropyl)-pyrido- [2,3-b] [1, 5] benzodiazepin- (6H) -on-5, deren Salze und Verfahren zu ihrer Herstellung | |
DD246299A5 (de) | Verfahren zur herstellung n-substituierter anziridin-2-carbonsaeurederivaten | |
DE2423725A1 (de) | 5-phenyl-4-oxo-delta hoch 2,alphathiazolidinessigsaeureester | |
DE1768505B2 (de) | Phenathylaminverbindungen und Ver fahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OI | Miscellaneous see part 1 | ||
OD | Request for examination | ||
AG | Has addition no. |
Ref country code: DE Ref document number: 2611690 Format of ref document f/p: P Ref country code: DE Ref document number: 2543821 Format of ref document f/p: P |
|
D2 | Grant after examination | ||
AG | Has addition no. |
Ref country code: DE Ref document number: 2543821 Format of ref document f/p: P |
|
AG | Has addition no. |
Ref country code: DE Ref document number: 2611690 Format of ref document f/p: P |